Cancer Stem Cells: Advances in Biology and Clinical Translation - VIRTUAL CONTENT AVAILABLE ON DEMAND
Organizer(s): Irene Oi Lin Ng, Xin Wei Wang and Dean G. TangDate: May 19 - 21, 2021
Location: Virtual at your computer. Recorded presentation content is available On Demand.
For important information on the coronavirus, please click here
Preponderant experimental and clinical evidence has demonstrated that pervasive cancer cell heterogeneity in both phenotypic presentations and functional properties exists, such that a population of cancer cells with cardinal stem cell properties (i.e., cancer stem cells) pre-exists in untreated tumors and spatiotemporally evolves during tumor progression and therapeutic interventions. Recent studies have also revealed significant phenotypic and functional plasticity in cancer cells, regulated by both genetic networks and epigenetic mechanisms. Both cancer cell heterogeneity and plasticity constitute major barriers to effective and durable clinical treatments. Ever since the revival of the cancer stem cell research field in the last two decades, we have made great strides in identifying and elucidating the biology of cancer stem cells in virtually all tumor systems. Significant progress has also been made in understanding how cancer stem cells interact with the cellular constituents and soluble factors in the proinflammatory and immune-suppressive tumor microenvironment. Facilitated by an explosion of technical advances in recent years, especially single-cell RNA-seq, we are achieving an unprecedented appreciation of the complexity of the cellular heterogeneity of human tumors. Significantly, novel therapeutic strategies that target cancer stem cells and cancer cell heterogeneity and plasticity are rapidly progressing to the clinical arena. This conference is organized to recapitulate these recent advances in our understanding of cancer stem cell biology and, importantly, the clinical translation of targeting cancer stem cells.
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA261003-01
Funding for this conference was made possible (in part) by 1R13CA261003-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.